FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma

Regeneron Pharmaceuticals, Inc . REGN and partner Sanofi SNY announced that the FDA has accepted for review the supplemental Biologics License Application (sBLA) of Dupixent (dupilumab) as an add-on maintenance treatment in adults and adolescents (12 years of age or older) with moderate-to-severe asthma.

The FDA has set a target action date of Oct 20, 2018 per the Prescription Drug User Fee Act. The sBLA was supported by results from the three pivotal trials from the LIBERTY ASTHMA clinical development program.

We note that Dupixent was approved in the United States in March 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent is also approved for use in certain patients with moderate-to-severe atopic dermatitis in a number of other countries, including the European Union, Canada and Japan.

Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Dupixent sales came in at $139 million in the fourth quarter. A potential label expansion of the drug will further boost results.

Meanwhile, Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases driven by Type 2 inflammation, including pediatric atopic dermatitis (phase III), nasal polyps (phase III) and eosinophilic esophagitis (phase III).

Regeneron's stock has lost 33.8% in the last six months compared with the industry 's 9.8% decline.

Regeneron's growth driver Eylea continues to perform well. Regeneron has co-developed Eylea with the HealthCare unit of Bayer AG BAYRY . The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales. The action date set by the FDA is Aug 11, 2018.

Zacks Rank & Another Key Pick

Regeneron currently sports a Zacks Rank #1 (Strong Buy).

Another top-ranked stock in the health care sector is Ligand Pharmaceuticals Inc. LGND which carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Ligand's earnings per share estimates have moved up from $3.78 to $4.15 for 2018 in the last 30 days. The company delivered a positive earnings surprise in three out of the trailing four quarters, with an average beat of 24.88%.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY): Free Stock Analysis Report

Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More